arrow
E

Elisabetta Abruzzese

Tor Vergata University
H指数:52
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project

评估慢性髓性白血病(CML)患者从高剂量到低剂量抑制剂转换的影响:降级影响(D-IMPACT)项目

Cancers
IF4.4
2026-05-200
OA
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study

美洛替尼在鲁索利替尼治疗失败后的临床获益及疗效预测因素:一项合作性真实世界研究

Cancer
IF5.1
2026-05-120
OAAI
Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison

与最佳可用疗法相比,在既往接受过鲁索利替尼治疗的患者中,使用莫美洛替尼的总体生存率:一项匹配调整的间接比较

2026-02-210
OAAI
Tracking leukemic residuals: dissecting the inverse relationship between CD26+stem cells and extracellular BCR::ABL1 transcript in Chronic Myeloid Leukemia (CML)

追踪白血病残留病灶:解析慢性髓性白血病(CML)中CD26+干细胞与细胞外BCR::ABL1转录本之间的反比关系

2025-12-010
OAAI
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint

尼洛替尼与伊马替尼治疗新诊断慢性髓性白血病患者的比较,包括早期从伊马替尼转换为尼洛替尼以实现治疗缓解的首次主要终点分析

Leukemia
IF13.4
2025-11-180
OAAI
GIMEMA survey on the management of chronic myeloid leukemia patients in the third line and beyond: insights from Italian hematologists

GIMEMA关于慢性髓性白血病患者在第三线及以后治疗管理情况的调查:来自意大利血液学家的见解

2025-11-180
OAAI
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study

阐明慢性髓性白血病患者诊断时外周血白血病干细胞临床作用:FLOWERS前瞻性研究的最终结果

Cancer
IF5.1
2025-10-150
OAAI
Revised “iRR6” model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib

修订后的“iRR6”模型在风险分层为1级的骨髓纤维化患者中使用鲁索利替尼治疗

Cancer
IF5.1
2025-08-210
OAAI
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study

在Nilotinib减量后的慢性期慢性髓性白血病中的无治疗缓解:DANTE研究的96周更新

2025-08-080
OAAI
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

Pelabresib联合ruxolitinib治疗JAK抑制剂初治骨髓纤维化:一项随机III期试验

2025-03-102
OA
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis

疾病表型显著影响慢性期骨髓纤维化患者停用鲁索利替尼后的结局

2025-03-040
OAAI
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
2025-01-200
OAAI
Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

酪氨酸激酶抑制剂在慢性髓性白血病中的停药:意大利673例患者的观察性研究

BLOOD
IF23.1
2024-11-050
PRE
ASXLI Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

ASXLI突变在诊断时并未影响慢性期(CP)慢性粒细胞白血病(CML)患者(pts)在SUSTRENIM临床试验中接受尼洛替尼(NIL)一线治疗或伊马替尼(IM)联合早期切换至尼洛替尼(NIL)(在无最佳应答情况下)的分子应答深度(MR)及无治疗缓解(TFR)资格。

BLOOD
IF23.1
2024-11-051
PRE
Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50-60 Years: A Campus CML Study

基线特征、治疗选择及早期一线TKI永久停药在50-60岁新诊断慢性髓性白血病患者中的研究:一项Campus CML研究

BLOOD
IF23.1
2024-11-050
PRE